Trastuzumab emtansine, [7] [8] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) …

The antibody portion binds to HER2, a protein found in high levels on some cancer cells and causes them to grow, and delivers a drug called emtansine (or DM-1), a microtubule inhibitor, …

Nov 15, 2024 · Ado-trastuzumab emtansine is used to treat a HER2-positive breast cancer. ado-trastuzumab emtansine is used both for early breast cancer and for breast cancer that has …

Trastuzumab emtansine is a type of targeted cancer drug. It is a treatment for HER2 positive breast cancer. Find out about how you have it, possible side effects and other important …

Learn how certain types of breast cancer can be treated with trastuzumab emtansine (Kadcyla, TDM1). Find out who it’s for and the possible side effects. 0808 800 6000

Nov 8, 2012 · Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the …

Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have previously received other medicines (eg, …

Jan 15, 2025 · The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T …

Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to …

Apr 22, 2024 · Kadcyla (ado-trastuzumab emtansine) is used to treat HER2-positive breast cancer. Includes Kadcyla side effects, interactions and indications.